CorMedix Form 4 / Janet Dillione ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dillione Janet

(Last)

(First)

(Middle)

C/O CORMEDIX INC.

400 CONNELL DRIVE, SUITE 5000

(Street)

BERKELEY HEIGHTS

07922

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/16/2019		P		6,147	A	$8.19⁽¹⁾	53,473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock	$0	08/14/2019		A		945		⁽²⁾	⁽²⁾	Common Stock	945	$0	945	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	1,126		1,126	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	843		843	D
Stock Option (Right to Buy Common Stock)	$8.3							⁽³⁾	01/10/2029	Common Stock	15,000		15,000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	1,328		1,328	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	2,728		2,728	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	7,500		7,500	D
Stock Option (Right to Buy Common Stock)	$2.85							⁽⁴⁾	02/16/2028	Common Stock	8,000		8,000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	2,679		2,679	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	3,125		3,125	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	4,167		4,167	D
Stock Option (Right to Buy Common Stock)	$11.2							⁽⁵⁾	02/21/2027	Common Stock	8,000		8,000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	695		695	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	829		829	D
Stock Option (Right to Buy Common Stock)	$15.15							⁽⁶⁾	08/11/2025	Common Stock	10,000		10,000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	283		283	D
Stock Option (Right to Buy Common Stock)	$15.15							⁽⁷⁾	02/21/2026	Common Stock	19,000		19,000	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	767		767	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	554		554	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	867		867	D
Phantom Stock	⁽²⁾							⁽²⁾	⁽²⁾	Common Stock	3,062		3,062	D

Explanation of Responses:

1. Represents the weighted average purchase price of the shares purchased ranging from a low of $8.179 to a high of $8.199 per share.

2. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director.

3. These options were granted on 01/10/2019. The options vest monthly with 100% vesting on the one-year anniversary of the date of grant, subject to continued service on the board.

4. These options were granted on 2/16/2018. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.

5. These options were granted on 2/21/2017. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.

6. These options were granted on 8/12/2015. The options vest as follows: 1/3 on 8/12/2015, 1/3 on 8/12/2016, and 1/3 on 8/12/2017.

7. These options were granted on 2/21/2016. These options vest in full on the first anniversary of the date of grant, subject to continued service on the board.

	/s/ Alexander M. Donaldson, by Power of Attorney	08/16/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CorMedix (CRMD) Form 4CorMedix / Janet Dillione ownership change